Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
50,808,497
-
Share change
-
+2,712,136
-
Total reported value
-
$415,724,914
-
Price per share
-
$8.19
-
Number of holders
-
65
-
Value change
-
+$29,078,237
-
Number of buys
-
36
-
Number of sells
-
19
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q3 2017
As of 30 Sep 2017,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
50,808,497 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, Capital World Investors, FMR LLC, ORBIMED ADVISORS LLC, BAILLIE GIFFORD & CO, RENAISSANCE TECHNOLOGIES LLC, Tekla Capital Management LLC, Rock Springs Capital Management LP, and QVT Financial LP.
This page lists
65
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.